Objective: To study the influence of prenatal ceftriaxone sodium intervention on pregnancy outcomes in GBS positive pregnant women during pregnancy. Methods: From January 2023 to January 2025, 60 pregnant women who underwent prenatal examination in the hospital and were diagnosed as positive GBS were selected as research subjects, and were divided into observation group (n=30) and control group (n=30) by random number table method. The pregnant women in the observation group were given intravenous infusion of ceftriaxone sodium near the time of labor or after premature rupture of membranes, while the pregnant women in the control group were given intravenous infusion of cefuroxime. The maternal-infant outcomes and changes of inflammatory response (white blood cell count, C-reactive protein), before and after treatment were compared between the two groups. Results: The incidence rate of puerperal infection and total incidence rate in observation group were significantly lower than those in control group (3.33% VS 20.00%, 10.00% VS 46.67%, both P<0.05). The incidence rate of GBS infectious diseases and total incidence rate were significantly lower in observation group than those in control group (0.00% VS 13.33%, 20.00% VS 56.67%, both P<0.05). On the 1st day after delivery, the white blood cell count and C-reactive protein in the two groups were significantly increased compared with those near the time of labor (P<0.05), but the increases in observation group were significantly lower than those in control group (P<0.05). Conclusion: For GBS positive pregnant women during pregnancy, prenatal application of ceftriaxone sodium for intervention can more effectively reduce the incidence rates of puerperal infection and neonatal GBS-related diseases, improve the maternal-infant outcomes, relieve the inflammatory response of pregnant women, with significant clinical application value.